UNSPSC 51281674: Streptomycin hydrochloride

This classification denotes an aminoglycoside antibiotic with the molecular structure C21H39N7O12.3CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 8P331B9592 chemically known as d-streptamine, o-2-deoxy-2-(methylamino)-.alpha.-l-glucopyranosyl-(1->2)-o-5-deoxy-3-c-formyl-.alpha.-l-lyxofuranosyl-(1->4)-n,n'-bis(aminoiminomethyl)-, trihydrochloride, but more commonly known as streptomycin hydrochloride, which bears US NIH Compound Identifier 197844.

UNSPSC 51281674 Streptomycin hydrochloride is a Commodity code for a specific antibiotic pharmaceutical product, but the recent state and local opportunities tagged under this code do not reflect procurement of streptomycin hydrochloride itself. Instead, the tagged records document awards and solicitations for unrelated pharmaceuticals—doxycycline hyclate, ciprofloxacin hydrochloride, and naloxone—suggesting a classification mismatch in the source data. The code shows little relevant recent activity aligned with its nominal scope of streptomycin hydrochloride supply.

The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, for doxycycline hyclate and ciprofloxacin hydrochloride totaling $2,999,999.11 over the contract life, but this is a completed award rather than an open opportunity. Seminole County, Florida released an IFB on June 30, 2026, for naloxone and drug deactivation systems with a July 26, 2023 response deadline (the date appears erroneous in the source). State and local buyers soliciting under this code include health departments and county community health organizations, with procurement vehicles ranging from IFB to cooperative purchasing agreements. Without open opportunities explicitly requesting streptomycin hydrochloride supply, the code does not present actionable current activity for business development targeting this specific pharmaceutical.